<DOC>
	<DOCNO>NCT00878111</DOCNO>
	<brief_summary>The main objective trial document safety antivascular effect escalate dos NGR-hTNF , 60 mcg/sqm 325 mcg/sqm , patient affect advanced metastatic solid tumor amenable standard therapy . Safety establish clinical laboratory assessment accord NCI-CTCAE criterion ( version 4.02 ) .</brief_summary>
	<brief_title>Study NGR-hTNF Administered High Doses Patient With Advanced Metastatic Solid Tumour</brief_title>
	<detailed_description>Pre-clinical study provide support NGR-TNF endow higher therapeutic index animal model study mechanism action show NGR-TNF induce tumour necrosis use relatively high dos . Recently , phase I dose-escalation study NGR-hTNF explore dose range 0.2 60 µg/m2 , show DLT 60 mcg/m2 experience transient acute infusion reaction minute first administration start . Considering relationship infusion event , dose escalation explore present phase I study use long infusion time ( i.e. , 120 minute instead 60 minute ) mild premedication . The first cohort ( n=4 ) patient treat NGR-hTNF administer 60 mcg/m2 IV every three week , dose level 33 % high MTD recommend dose select previous phase I trial ( i.e. , 45 mcg/m2 ) . If ≤1 4 patient experience DLT first cycle , follow cohort treat escalate dos ( 80 325 mcg/m2 ) NGR-hTNF IV every three week .</detailed_description>
	<criteria>Patients ≥18 year select metastatic solid tumour recognize highly vascularise amenable clinical improvement current standard treatment Colorectal cancer ( CRC ) patient previously resistant standard systemic regimen ( include biologic agent ) Gastric cancer ( GC ) patient treat two standard systemic regimen metastatic disease Hepatocellular carcinoma ( HCC ) patient previously resistant standard systemic regimen Pancreatic carcinoma ( PC ) patient treat one standard systemic regimen metastatic disease Non small cell lung carcinoma ( NSCLC ) patient treat two standard systemic regimen ( include biologic agent ) metastatic disease Neuroendocrine ( NE ) tumours refractory somatostatin analogue treatment Other rare tumour include malignant pleural mesothelioma ( MPM ) , softtissue sarcoma ( STS ) , renal cell carcinoma ( RCC ) , resistant/refractory current standard treatment Life expectancy 3 month ECOG Performance status 01 Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Creatinine clearance ( estimate accord CockcroftGault formula ) ≥ 50 ml/min Patients may prior therapy provide follow condition meet treatment start : Chemotherapy , radiation therapy , hormonal therapy , immunotherapy : washout period 28 day Surgery : washout period 14 day Patients must give write informed consent participate study . Concurrent anticancer therapy Patients must receive investigational agent study Patients myocardial infarction within last six ( 6 ) month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Uncontrolled hypertension Prolonged QTc interval ( congenital acquire ) &gt; 450 ms Patient significant peripheral vascular disease History evidence upon physical examination CNS disease unless adequately treat ( e.g. , primary brain tumor , brain metastasis , seizure control standard medical therapy ) , history stroke Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction contraindication human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>High dos</keyword>
</DOC>